Hospital

Gretchen Garofoli, PharmD, an associate professor at the West Virginia School of Pharmacy, discusses the current recommendations for COVID-19, respiratory syncytial virus (RSV), and influenza vaccines and vaccine hesitancy.

Findings may have therapeutic implications because of the potential to target neurotransmitters to treat or prevent melanoma.

Results of phase 3 trials could lead to the approval of remibrutinib to provide more effective and controlled treatment of chronic spontaneous urticaria than H1-antihistamines.

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.

Policy efforts must be put in place to support HCV treatment for all individuals to reduce the disparities in direct-acting antiviral treatment.

There was no association between the amount of evidence behind a product and the time until Medicare coverage, suggesting issues within the coverage determination process itself.

After repeated treatment with packed red blood cell transfusions, treatment with intravenous immunoglobulin in a child with parvovirus B19 infection successfully resolved the infection and negated the need for further transfusions.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

With the continued advancement and approval of cell and gene therapies, the need for trustworthy microbiology quality control solutions is at an all-time high.

Lack of information and access to health care, stigma, discrimination, criminalization, and privacy concerns are among the barriers some groups face when trying to obtain preventative HIV medications.

Researchers found an increase in patients with melanoma who experience chronic immune-related adverse effects at 18 months compared to a previous study with a follow-up point of 6 months.

Adding human papillomavirus genotypes to the predictive model had a significantly higher effect in improving accuracy compared to adding epidemiological factors and pelvic examination.

Though an association was found between depression and anxiety and lung cancers, there were no connections found to overall, breast, prostate, colorectal, and alcohol-related cancers.

Lisaftoclax is a novel, oral, small-molecule, BCL-2 selective inhibitor being evaluated for treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The burden of aging-related comorbidities was higher across every age category in women compared to men, and increased with age.

Improved prescription information could help consumers make better health care decisions and result in cost savings.

Study results showed no significant association between those who bite their nails and SARS-CoV-2 infection, in addition to a lower rate of infection for those who wear glasses compared to those who don’t wear glasses.

In addition to the low use of structured surveillance overall, modified CHEST criteria only identified a small portion of patients with subsegmental pulmonary embolism eligible to receive structural surveillance.

Adults aged 80 years and older and those living in areas with worse economic conditions are more likely to receive potentially inappropriate medications in the outpatient setting, which may be associated with cognitive impairment.

Study finds patients with cancer feel reassured that biosimilars provide a safe, adequate, and cost-effective alternative to the pricier reference drug.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

Updated guidelines, comprehensive review, and an investment of resources into pediatric preventive cardiology programs could help provide successful care.

At a median follow-up of 48.7 months, pembrolizumab monotherapy produced an investigator-assessed objective response rate of 41.5% and a 20.8% complete response rate in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

New innovations are revolutionizing diagnostics and optimizing treatment outcomes, marking significant strides in the fight against digestive diseases.

The findings suggest that CHD1L’s could provide treatment opportunities for individuals infected with HIV-1.

CDI is difficult to contain in health care settings because some patients are unknowing carriers of the toxigenic strains of the infection.

Notably, obesity was not independently associated with pulmonary pressure or decreased right ventricle load stress despite being a condition related to diabetes.

However, the FDA said an application for zuranolone to treat major depressive disorder did not provide substantial evidence of efficacy.